Allergan again rebuffed advances from Valeant Pharmaceuticals, saying that its board has unanimously determined that the unsolicited exchange offer to buy the Botox maker is "grossly inadequate."
from WSJ.com: US Business http://ift.tt/1p9UKJt
via IFTTT
from WSJ.com: US Business http://ift.tt/1p9UKJt
via IFTTT
No comments:
Post a Comment